PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-2 (2)
 

Clipboard (0)
None

Select a Filter Below

Journals
Authors
more »
Year of Publication
Document Types
author:("chella, Mario")
1.  Di-(2-ethylhexyl) phthalate and autism spectrum disorders 
ASN NEURO  2012;4(4):e00089.
ASDs (autism spectrum disorders) are a complex group of neurodevelopment disorders, still poorly understood, steadily rising in frequency and treatment refractory. Extensive research has been so far unable to explain the aetiology of this condition, whereas a growing body of evidence suggests the involvement of environmental factors. Phthalates, given their extensive use and their persistence, are ubiquitous environmental contaminants. They are EDs (endocrine disruptors) suspected to interfere with neurodevelopment. Therefore they represent interesting candidate risk factors for ASD pathogenesis. The aim of this study was to evaluate the levels of the primary and secondary metabolites of DEHP [di-(2-ethylhexyl) phthalate] in children with ASD. A total of 48 children with ASD (male: 36, female: 12; mean age: 11±5 years) and age- and sex-comparable 45 HCs (healthy controls; male: 25, female: 20; mean age: 12±5 years) were enrolled. A diagnostic methodology, based on the determination of urinary concentrations of DEHP metabolites by HPLC-ESI-MS (HPLC electrospray ionization MS), was applied to urine spot samples. MEHP [mono-(2-ethylhexenyl) 1,2-benzenedicarboxylate], 6-OH-MEHP [mono-(2-ethyl-6-hydroxyhexyl) 1,2-benzenedicarboxylate], 5-OH-MEHP [mono-(2-ethyl-5-hydroxyhexyl) 1,2-benzenedicarboxylate] and 5-oxo-MEHP [mono-(2-ethyl-5-oxohexyl) 1,2-benzenedicarboxylate] were measured and compared with unequivocally characterized, pure synthetic compounds (>98%) taken as standard. In ASD patients, significant increase in 5-OH-MEHP (52.1%, median 0.18) and 5-oxo-MEHP (46.0%, median 0.096) urinary concentrations were detected, with a significant positive correlation between 5-OH-MEHP and 5-oxo-MEHP (rs = 0.668, P<0.0001). The fully oxidized form 5-oxo-MEHP showed 91.1% specificity in identifying patients with ASDs. Our findings demonstrate for the first time an association between phthalates exposure and ASDs, thus suggesting a previously unrecognized role for these ubiquitous environmental contaminants in the pathogenesis of autism.
doi:10.1042/AN20120015
PMCID: PMC3363982  PMID: 22537663
autism; di-(2-ethylhexyl) phthalate; endocrine disrupters; HPLC-ESI-MS urine analysis; secondary metabolites; ASD, autism spectrum disorder; CARS, childhood autism rating scale; CI, confidence interval; DEHP, di-(2-ethylhexyl) phthalate; ED, endocrine disruptor; HC, healthy control; HPLC-ESI-MS, HPLC electrospray ionization MS; MEHP, mono-(2-ethylhexenyl) 1,2-benzenedicarboxylate; 5-OH-MEHP, mono-(2-ethyl-5-hydroxyhexyl) 1,2-benzenedicarboxylate; 6-OH-MEHP, mono-(2-ethyl-6-hydroxyhexyl) 1,2-benzenedicarboxylate; OS, oxidative stress; 5-oxo-MEHP, mono-(2-ethyl-5-oxohexyl) 1,2-benzenedicarboxylate; QC, quality control; RP-HPLC-ESI-MS, reverse-phase HPLC-ESI-MS; ROC, receiver operating characteristic; SPE, solid phase extraction; PPARα, peroxisome-proliferator-activated receptor α; TH, thyroid hormone
2.  Glycopeptide-Based Antibody Detection in Multiple Sclerosis by Surface Plasmon Resonance 
Sensors (Basel, Switzerland)  2012;12(5):5596-5607.
In multiple sclerosis (MS) the gold standard for the diagnosis and prognosis is, up to now, the use of magnetic resonance imaging markers. No alternative simpler assays proven of use, except for cerebrospinal fluid analysis, have been provided in MS diagnosis. Therefore, there is a need to develop non-invasive, sensitive, simple new techniques for the clinical routine. Herein we present the evaluation of the feasibility of a glycopeptide-based biosensor to detect MS specific antibodies in sera using the surface plasmon resonance technology. The previously described glycopeptide antigen CSF114(Glc) has been immobilized on a gold sensor chip and the method has been optimized for real-time specific autoantibody detection directly in sera. A population of 60 healthy blood donors and 61 multiple sclerosis patients has been screened. The receiver operating characteristic (ROC)-based analysis has established the optimal diagnostic cut-off value for the method obtaining a sensitivity of 36% and a specificity of 95%. Sample sera have been also screened with a previously validated ELISA.
doi:10.3390/s120505596
PMCID: PMC3386702  PMID: 22778603
multiple sclerosis; surface plasmon resonance; serodiagnosis; biacore; immunoassay; glycopeptide CSF114(Glc)

Results 1-2 (2)